[go: up one dir, main page]

CA2310269A1 - Molecules d'immunoglobuline a partie variable de synthese et a specificite modifiee - Google Patents

Molecules d'immunoglobuline a partie variable de synthese et a specificite modifiee Download PDF

Info

Publication number
CA2310269A1
CA2310269A1 CA002310269A CA2310269A CA2310269A1 CA 2310269 A1 CA2310269 A1 CA 2310269A1 CA 002310269 A CA002310269 A CA 002310269A CA 2310269 A CA2310269 A CA 2310269A CA 2310269 A1 CA2310269 A1 CA 2310269A1
Authority
CA
Canada
Prior art keywords
modified immunoglobulin
receptor
antigen
cdr
immunoglobulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002310269A
Other languages
English (en)
Inventor
Ronald M. Burch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Euro Celtique SA
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2310269A1 publication Critical patent/CA2310269A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C07K16/4266—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/18—Kallidins; Bradykinins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne des molécules d'immunoglobuline modifiées, notamment des anticorps, qui se lient de manière immunospécifique à un élément d'une paire de liaison, lesquelles immunoglobulines présentent une partie variable renfermant une ou plusieurs régions déterminantes de la complémentarité renfermant la séquence nucléotidique d'un site de liaison pour cet élément de la paire de liaison, lequel site est dérivé de l'autre élément de la paire de liaison, et que l'on ne trouve pas à l'état naturel dans la région déterminante de la complémentarité. L'invention concerne également l'utilisation thérapeutique et diagnostique de l'immunoglobuline modifiée.
CA002310269A 1997-11-14 1998-11-13 Molecules d'immunoglobuline a partie variable de synthese et a specificite modifiee Abandoned CA2310269A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US6571697P 1997-11-14 1997-11-14
US60/065,716 1997-11-14
US8140398P 1998-04-10 1998-04-10
US60/081,403 1998-04-10
PCT/US1998/024302 WO1999025378A1 (fr) 1997-11-14 1998-11-13 Molecules d'immunoglobuline a partie variable de synthese et a specificite modifiee

Publications (1)

Publication Number Publication Date
CA2310269A1 true CA2310269A1 (fr) 1999-05-27

Family

ID=26745908

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002310269A Abandoned CA2310269A1 (fr) 1997-11-14 1998-11-13 Molecules d'immunoglobuline a partie variable de synthese et a specificite modifiee
CA002309990A Abandoned CA2309990A1 (fr) 1997-11-14 1998-11-13 Anticorps modifies a capacite amelioree de declenchement d'une reponse anti-idiotype

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA002309990A Abandoned CA2309990A1 (fr) 1997-11-14 1998-11-13 Anticorps modifies a capacite amelioree de declenchement d'une reponse anti-idiotype

Country Status (9)

Country Link
EP (2) EP1032420A4 (fr)
JP (2) JP2001526021A (fr)
KR (2) KR20010015817A (fr)
CN (2) CN1294517A (fr)
AU (2) AU763029B2 (fr)
BR (2) BR9815289A (fr)
CA (2) CA2310269A1 (fr)
IL (2) IL136114A0 (fr)
WO (2) WO1999025379A1 (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU753753B2 (en) * 1998-11-13 2002-10-24 Euro-Celtique S.A. Contraceptive antibody vaccines
EP2169073B1 (fr) * 1999-10-11 2013-11-13 Institut Pasteur Vecteurs pour la préparation des compositions immunotherapeutiques
WO2001088159A2 (fr) * 2000-05-16 2001-11-22 Euro-Celtique S.A. Anticorps synthetique cd28 servant a la modulation de responses immunitaires
US7396917B2 (en) 2000-12-05 2008-07-08 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
ES2258558T3 (es) * 2000-12-05 2006-09-01 Alexion Pharmaceuticals, Inc. Anticuerpos diseñados racionalmente.
GB0103174D0 (en) * 2001-02-08 2001-03-28 Smithkline Beecham Plc Novel method of treatment
AU2002307064A1 (en) * 2001-04-02 2002-10-15 Purdue Pharma L.P. Immunoglobulin construct containing anti-mucin variable domain sequences for eliciting an anti-idiotype anti-tumor response
AU2002365926A1 (en) * 2001-10-25 2003-09-02 Euro-Celtique S.A. Compositions and methods directed to anthrax toxin
ATE382367T1 (de) * 2002-04-09 2008-01-15 Univ Missouri Behandlung des typ 1 diabetes vor und nach expression von prädispositionsmarkern
CA2484000A1 (fr) 2002-05-24 2003-12-04 Schering Corporation Anticorps anti-igfr humain neutralisant
AR040778A1 (es) * 2002-08-06 2005-04-20 Glaxo Group Ltd Anticuerpos alterados o fragmentos funcionales que se unen a mag (glicoproteina asociada a mielina).
EP1578447A4 (fr) 2002-10-31 2009-06-03 Genentech Inc Methodes et compositions pouvant augmenter la production d'anticorps
GB0306309D0 (en) 2003-03-19 2003-04-23 Glaxo Group Ltd Method of treatment
WO2005021595A1 (fr) * 2003-08-28 2005-03-10 Euro-Celtique S.A. Procedes utilisant les regles des regions de presentation des anticorps pour intervenir sur des anticorps
JP2007510434A (ja) 2003-11-12 2007-04-26 シェーリング　コーポレイション 多重遺伝子発現のためのプラスミドシステム
PE20050928A1 (es) 2003-11-21 2005-11-08 Schering Corp Combinaciones terapeuticas de anticuerpo anti-igfr1
AU2005219322B2 (en) * 2004-03-09 2008-09-18 Kyoto University Pharmaceutical Composition Comprising CXCR3 Inhibitor
ES2356830T3 (es) 2004-12-03 2011-04-13 Schering Corporation Biomarcadores para preselección de pacientes para terapia de anti-igf-1r.
CN101663321B (zh) * 2006-08-28 2014-10-08 协和发酵麒麟株式会社 拮抗型人light特异性人源性单克隆抗体
GB0706070D0 (en) * 2007-03-28 2007-05-09 Scancell Ltd Nucleic acids
AR070821A1 (es) * 2008-03-12 2010-05-05 Imclone Llc Anticuerpo anti- tyrp1 (antitiroxina humana)
EP2799453B1 (fr) * 2009-04-29 2019-04-03 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. ERG2 anticorps monoclonaux et leur utilisation thérapeutique
CN102816240B (zh) * 2011-03-08 2014-02-12 中国人民解放军第三军医大学第二附属医院 一种融合蛋白及其融合蛋白表达载体
WO2012166712A1 (fr) 2011-05-27 2012-12-06 Fox Chase Cancer Center Anticorps dirigés contre le récepteur de type ii d'une substance inhibitrice anti-mullérienne conçue de façon rationnelle
LT2782598T (lt) * 2011-11-23 2020-07-27 In3Bio Ltd. Rekombinantiniai baltymai ir jų terapinis panaudojimas
JP5437525B1 (ja) 2012-12-28 2014-03-12 株式会社ナード研究所 チロシン誘導体およびチロシン誘導体の製造方法
WO2014183649A1 (fr) * 2013-05-14 2014-11-20 上海亨臻实业有限公司 Vaccin à base d'épitopes pour protéine de faible immunogénicité et son procédé de préparation et d'utilisation
CN103275914B (zh) * 2013-06-03 2015-04-01 中国人民解放军军事医学科学院微生物流行病研究所 展示保护性抗原的细菌菌蜕及其应用
CN105263953B (zh) * 2014-01-15 2020-01-07 勃林格殷格翰动物保健美国有限公司 猪细小病毒5a、使用方法及疫苗
AU2015263286B2 (en) * 2014-05-19 2020-03-12 Valo Therapeutics Oy Coated oncolytic adenoviruses for cancer vaccines
CN105693859B (zh) * 2016-03-22 2019-06-21 苏州莱泰生物科技有限公司 抗人g2a单克隆抗体以及检测人巨噬细胞g2a表达量的试剂盒
CN111978382B (zh) * 2020-09-03 2022-03-04 吉林大学第一医院 一种球形孢子丝菌Gp70重组蛋白的制备方法及其应用
CN112646029B (zh) * 2020-12-30 2022-07-29 深圳清华大学研究院 成熟脑源性神经营养因子的抗体及其应用和诊断试剂盒
CN115856296B (zh) * 2022-12-16 2023-07-25 华北理工大学 抗志贺氏菌的单克隆抗体及其检测中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688657A (en) * 1988-03-31 1997-11-18 International Bio-Immune Systems, Inc. Monoclonal antibodies against human colon carcinoma-associated antigens and uses therefor
DE69023900D1 (de) * 1989-02-24 1996-01-11 Univ California Gentechnologisch veränderte immunglobuline.
GB9019553D0 (en) * 1990-09-07 1990-10-24 Unilever Plc Specific binding agents
GB9109645D0 (en) * 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
GB9223084D0 (en) * 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
EP0674710B1 (fr) * 1992-11-16 2003-05-02 Cancer Research Fund Of Contra Costa Peptides à large spécificité néoplastique
WO1994014848A1 (fr) * 1992-12-24 1994-07-07 The Regents Of The University Of California Immunoglobulines produites par genie genetique
WO1994014847A1 (fr) * 1992-12-24 1994-07-07 The Regents Of The University Of California Immunoglobulines produites par genie genetique
US5476784A (en) * 1993-04-06 1995-12-19 Rice; Peter A. Gonococcal anti-idiotypic antibodies and methods and compositions using them
US5653977A (en) * 1993-09-09 1997-08-05 Uab Research Foundation Anti-idiotypic antibody that mimics the GD2 antigen
US5624904A (en) * 1993-11-17 1997-04-29 Massachusetts Institute Of Technology Method for treating gram positive septicemia

Also Published As

Publication number Publication date
EP1030684A1 (fr) 2000-08-30
JP2002507544A (ja) 2002-03-12
IL136114A0 (en) 2001-05-20
AU763029B2 (en) 2003-07-10
AU1459899A (en) 1999-06-07
EP1032420A1 (fr) 2000-09-06
KR20010015817A (ko) 2001-02-26
CA2309990A1 (fr) 1999-05-27
JP2001526021A (ja) 2001-12-18
EP1032420A4 (fr) 2004-09-15
AU2003252902A1 (en) 2003-11-06
IL136113A0 (en) 2001-05-20
WO1999025379A1 (fr) 1999-05-27
KR20010015818A (ko) 2001-02-26
AU1459799A (en) 1999-06-07
CN1294517A (zh) 2001-05-09
AU737457B2 (en) 2001-08-23
BR9815580A (pt) 2002-01-29
EP1030684A4 (fr) 2004-09-15
WO1999025378A9 (fr) 1999-08-12
CN1327388A (zh) 2001-12-19
BR9815289A (pt) 2001-12-26
WO1999025378A1 (fr) 1999-05-27

Similar Documents

Publication Publication Date Title
AU763029B2 (en) Immunoglobulin molecules having a synthetic variable region and modified specificity
US7915395B2 (en) Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US8603466B2 (en) Agonist antibodies against TSHR
CN118667027A (zh) 结合至cd137和psma的分子
US6482919B2 (en) Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
JPH06506362A (ja) 改変抗体可変領域の調製のための物質および方法ならびにその治療的用途
JP2935520B2 (ja) ガン治療に用いられる新規高親和性改変抗体系統群
JP2022532370A (ja) 結合分子
AU765585B2 (en) Antibodies to C3b(I) for delivery of diagnostic and therapeutic agents to cancer cells
WO2005021595A1 (fr) Procedes utilisant les regles des regions de presentation des anticorps pour intervenir sur des anticorps
AU737457C (en) Modified antibodies with enhanced ability to elicit an anti-idiotype response
MXPA00004582A (en) Immunoglobulin molecules having a synthetic variable region and modified specificity
CA2735433A1 (fr) Anticorps anti-glycosphingolipide de type i etendu, derives de celui-ci et utilisation
AU753753B2 (en) Contraceptive antibody vaccines
MXPA00004581A (en) Modified antibodies with enhanced ability to elicit an anti-idiotype response
AU9340701A (en) Modified antibodies with enhanced ability to elicit an anti-idiotype response

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued
FZDE Discontinued

Effective date: 20051114